Neurocrine/NBIX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Neurocrine
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Ticker
NBIX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
1,448
Website
www.neurocrine.com
Neurocrine Metrics
BasicAdvanced
$14B
Market cap
38.17
P/E ratio
$3.60
EPS
0.36
Beta
-
Dividend rate
Price and volume
Market cap
$14B
Beta
0.36
Financial strength
Current ratio
2.523
Quick ratio
2.33
Long term debt to equity
10.599
Total debt to equity
17.212
Interest coverage (TTM)
102.26%
Management effectiveness
Return on assets (TTM)
10.08%
Return on equity (TTM)
18.16%
Valuation
Price to earnings (TTM)
38.17
Price to revenue (TTM)
6.82
Price to book
5.78
Price to tangible book (TTM)
5.86
Price to free cash flow (TTM)
22.01
Growth
Revenue change (TTM)
23.99%
Earnings per share change (TTM)
456.75%
3-year revenue growth
23.77%
3-year earnings per share growth
-4.16%
What the Analysts think about Neurocrine
Analyst Ratings
Majority rating from 28 analysts.
Neurocrine Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$515M
0.02%
Net income
$43M
-70.62%
Profit margin
8.42%
-70.62%
Neurocrine Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.95
$0.82
$1.44
$0.42
-
Expected
$0.78
$0.97
$1.15
$1.01
$1.03
Surprise
22.24%
-15.12%
25.75%
-58.35%
-
Neurocrine News
AllArticlesVideos
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PRNewsWire·2 days ago
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PRNewsWire·4 weeks ago
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PRNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $14B as of July 03, 2024.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 38.17 as of July 03, 2024.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of July 03, 2024.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Neurocrine stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.